#Non-Hodgkin Lymphoma Therapeutics Market Share

[heathcareforallworld]

Bleomycin Market: Size, Share, and Industry Trends Forecasted Through 2032

Introduction

Bleomycin, a chemotherapeutic agent primarily used in the treatment of cancer, has been a critical drug in the oncology field for several decades. It is used to treat various cancers, including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular cancer, and certain types of skin cancer. The bleomycin market, like many other pharmaceutical markets, is influenced by factors such as the prevalence of cancer, advancements in treatment protocols, and evolving healthcare policies. This article delves into the size, share, industry trends, and forecast for the bleomycin market through 2032.

Market Size and Growth

Bleomycin Market Size was estimated at 2.06 (USD Billion) in 2023. The Bleomycin Market Industry is expected to grow from 2.13 (USD Billion) in 2024 to 2.8 (USD Billion) by 2032. The bleomycin Market CAGR (growth rate) is expected to be around 3.46% during the forecast period (2024 - 2032). This growth is driven by an increase in cancer incidence worldwide, advancements in drug formulations, and the growing adoption of combination therapies that include bleomycin.

The rising prevalence of cancer, particularly in developing regions, is a significant driver of the bleomycin market. Cancer continues to be a leading cause of morbidity and mortality globally, with millions of new cases diagnosed each year. This growing cancer burden has led to increased demand for effective chemotherapeutic agents, including bleomycin. Additionally, the growing geriatric population, which is more susceptible to cancer, is expected to further fuel the market's growth.

Market Share Analysis

North America currently holds the largest share of the bleomycin market. The region's dominance is attributed to its well-established healthcare infrastructure, high prevalence of cancer, and significant investments in research and development. The United States, in particular, is a major market for bleomycin due to its large patient population, strong healthcare system, and the presence of key pharmaceutical companies.

Europe follows North America in terms of market share, with countries like Germany, France, and the United Kingdom leading the region's market. The European market is supported by a high cancer incidence, robust healthcare systems, and increasing awareness about cancer treatment options. Moreover, favorable government policies and funding for cancer research and treatment contribute to the growth of the bleomycin market in Europe.

The region's rapid market expansion is driven by rising healthcare spending, improving healthcare infrastructure, and increasing awareness about cancer treatment. Countries like China, India, and Japan are key contributors to the growth of the bleomycin market in Asia-Pacific, supported by large populations and a growing focus on healthcare.

Industry Trends

Several key trends are shaping the bleomycin market:

Rising Cancer Incidence: The increasing prevalence of cancer globally is a major driver of the bleomycin market. Factors such as aging populations, lifestyle changes, and environmental factors contribute to the rising incidence of cancer, leading to higher demand for effective chemotherapy agents like bleomycin.

Advancements in Drug Formulations: The development of new and improved drug formulations is enhancing the efficacy and safety of bleomycin. Innovations in drug delivery systems, such as liposomal formulations and targeted drug delivery, are improving the therapeutic outcomes of bleomycin, attracting more healthcare providers to adopt these treatments.

Growing Adoption of Combination Therapies: Bleomycin is often used in combination with other chemotherapeutic agents to enhance its efficacy in cancer treatment. The growing trend of combination therapies, particularly in the treatment of Hodgkin’s lymphoma and testicular cancer, is driving the demand for bleomycin in the market.

Increasing Focus on Personalized Medicine: The shift towards personalized medicine in oncology is influencing the use of bleomycin. Personalized treatment approaches that consider the genetic makeup and specific characteristics of a patient's cancer are becoming more common. This trend is expected to impact the bleomycin market as more targeted and individualized treatment protocols are developed.

Regulatory Approvals and Expansions: Regulatory approvals for new indications and expanded uses of bleomycin are contributing to market growth. Pharmaceutical companies are focusing on gaining approvals for the use of bleomycin in additional cancer types and treatment settings, which is expected to drive the market's expansion.

Market Forecast

The bleomycin market is expected to continue growing through 2032, driven by the rising incidence of cancer, advancements in drug formulations, and the growing adoption of combination therapies. Key players in the market will need to focus on innovation, expanding their product offerings, and leveraging partnerships with research institutions and healthcare providers to stay competitive.

Key Market Segments: The bleomycin market can be segmented based on product type, application, distribution channel, and region. Product types include branded and generic versions of bleomycin. Applications encompass various cancer types, including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, testicular cancer, and others. Distribution channels include hospitals, specialty clinics, and online pharmacies. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Challenges: Despite the positive growth outlook, the bleomycin market faces challenges such as the risk of side effects, including pulmonary toxicity, and the availability of alternative cancer therapies. Additionally, the high cost of cancer treatment and potential competition from biosimilars and generics may impact market growth.

Conclusion

The bleomycin market is poised for significant growth through 2032, driven by the rising incidence of cancer, advancements in drug formulations, and the growing adoption of combination therapies. As the market evolves, key players will need to focus on innovation, expanding their product portfolios, and exploring new growth opportunities. The bleomycin market offers substantial opportunities for growth, particularly in emerging markets and through the development of new treatment protocols and drug formulations.Top of Form

[delveinsight12]

Central Nervous System Lymphoma Market to Witness Growth by 2032 | Companies- Novartis, Prelude Therapeutics, Kite, Celgene

DelveInsight's "Central Nervous System Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Central Nervous System Lymphoma, historical and forecasted epidemiology as well as the Central Nervous System Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Central Nervous System Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Central Nervous System Lymphoma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Central Nervous System Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Central Nervous System Lymphoma market.

Central Nervous System Lymphoma Overview

Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Central nervous system lymphoma is more common in men than women. the exact causes of CNS lymphoma are not known, there are several factors that may increase a person's risk for developing the disease, such as having a compromised immune system due to acquired immunodeficiency syndrome (AIDS), other disorders of the immune system, or chronic immunosuppression (a reduced function of the immune system) as a result of organ transplantation. To diagnose Central Nervous System lymphoma different tests are used to examine the eyes, brain and spinal cord. Physical exam and history, neurological exam to check mental status, coordination, ability to walk normally and how well the muscles, senses and reflexes work, slit-lamp eye exam - this test uses a special microscope with a bright, narrow slit of light to check the outside and inside of the eye. Vitrectomy - A surgical procedure in which some of the vitreous humor (the gel-like fluid inside the eyeball) is removed and examined under a microscope to check for cancer cells. Chest x-ray and CT scans of the chest and abdomen. MRI scans of the brain and spinal cord. There is no standard treatment for Central Nervous System lymphoma. Methotrexate-based combinations that include rituximab (Rituxan) have been the most successful for Central Nervous System lymphoma patients. Methotrexate is usually given at high doses and requires that the patient be hospitalized while giving the chemotherapy.

Learn more about Central Nervous System Lymphoma, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Central Nervous System Lymphoma Market Outlook 2032

Central Nervous System Lymphoma Market 

The Central Nervous System Lymphoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Central Nervous System Lymphoma market trends by analyzing the impact of current Central Nervous System Lymphoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Central Nervous System Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Central Nervous System Lymphoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Central Nervous System Lymphoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at: https://www.delveinsight.com/sample-request/central-nervous-system-lymphoma-market

Central Nervous System Lymphoma Epidemiology 

The Central Nervous System Lymphoma epidemiology section provides insights into the historical and current Central Nervous System Lymphoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Central Nervous System Lymphoma market report also provides the diagnosed patient pool, trends, and assumptions. 

Click here and explore more about Central Nervous System Lymphoma Epidemiology

Central Nervous System Lymphoma Drugs Uptake

This section focuses on the uptake rate of the potential Central Nervous System Lymphoma drugs recently launched in the Central Nervous System Lymphoma market or expected to be launched in 2019-2032. The analysis covers the Central Nervous System Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Central Nervous System Lymphoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Central Nervous System Lymphoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Key Central Nervous System Lymphoma Companies

• Shandong New Time Pharmaceutical

• PIQUR Therapeutics

• Ono Pharmaceutical

• Janssen, LP

• Kazia Therapeutics

• Beijing InnoCare Pharma Tech

• Celltrion

• Bristol Myers Squibb

• AstraZeneca

• Novartis

• Prelude Therapeutics

• Kite, A Gilead Company

• Celgene

Central Nervous System Lymphoma Pipeline Development Activities

The Central Nervous System Lymphoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Central Nervous System Lymphoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Central Nervous System Lymphoma pipeline development activities at: Central Nervous System Lymphoma Therapy Assessment

Central Nervous System Lymphoma Therapeutics Assessment

Major key companies are working proactively in the Central Nervous System Lymphoma Therapeutics market to develop novel therapies which will drive the Central Nervous System Lymphoma treatment markets in the upcoming years.

Get the Detailed TOC of the Central Nervous System Lymphoma Market report here: Central Nervous System Lymphoma Market

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology

[priyanshisingh]

Non-Hodgkin Lymphoma Therapeutics Market Analysis with Size, Revenue, Growth Drivers and Forecast to 2030

The latest market report published by Credence Research, Inc. “Global Non-Hodgkin Lymphoma Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global non-hodgkin lymphoma therapeutics market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 8.80% between 2023 and 2030. The market was valued at USD 8.5 billion in 2022 and is expected to reach USD 15.34 billion in 2030.

The global non-Hodgkin lymphoma (NHL) therapeutics market is expected to experience substantial growth in the coming years, driven by key factors such as the rising incidence of non-Hodgkin lymphoma, the expansion of potential pipeline medications, high diagnostic rates, and a susceptible pediatric population.

The report highlights that radiation therapy is currently the most popular type of therapy, accounting for over 43% of the market share in terms of value in 2022. However, the chemotherapy segment is expected to exhibit the fastest CAGR during the forecast period. Among cell types, B-cell lymphomas dominate the global demand for non-Hodgkin lymphoma therapeutics, holding a substantial share of over 80% in 2022 and projected to grow at a rapid CAGR.

Geographically, North America leads the global market growth, contributing to over one-third of the market share in 2022. The region's dominance is attributed to the high prevalence of various cancers, including non-Hodgkin lymphoma, as well as advanced diagnostic and treatment options. Asia Pacific and Europe collectively account for just under 50% of the market share, with Europe holding over 22% in 2022.

Non-Hodgkin Lymphoma (NHL) Therapeutics Market Major Challenges revolve around the complex nature of this hematologic malignancy and the ever-evolving landscape of treatment options. One significant challenge is the heterogeneity of the disease itself, as NHL encompasses a diverse group of lymphomas with varying clinical characteristics and genetic alterations. This intricacy poses difficulties in developing targeted therapies that can effectively combat each subtype. Additionally, another obstacle lies in the resistance mechanisms that tumors often develop over time, rendering certain treatments ineffective and necessitating continuous adaptation by researchers and clinicians alike.

Leading players in the global non-Hodgkin lymphoma therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Seattle Genetics, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., and Janssen Pharmaceuticals Inc. These companies are focused on product innovation, expanding their distribution channels, and strategic collaborations to maintain a competitive edge.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Non-Hodgkin Lymphoma Therapeutics Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Non-Hodgkin Lymphoma Therapeutics Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/non-hodgkin-lymphoma-therapeutics-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/pharmaceutical-glass-tubing-market

Related Report: https://www.credenceresearch.com/report/mesoporous-silica-nanoparticles-drugs-darketBrowse Our Blog:https://www.linkedin.com/pulse/asia-pacific-non-hodgkin-lymphoma-therapeutics-market-priyanshi-singh

[techsciresearch]

Non-Hodgkin Lymphoma Therapeutics Market to Grow with 10.02% CAGR until 2026 – TechSci Research

Increasing prevalence of Non-Hodgkin lymphomas (NHL) and other types of cancers to drive global Non-Hodgkin Lymphoma (NHL) therapeutics market

According to TechSci Research report, “Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2026”, the market was valued at USD7931.54 million in 2020 and is expected to reach USD14689.31 million in 2026 by witnessing double digit CAGR of 10.02% during the forecast period. The global Non-Hodgkin Lymphoma (NHL) therapeutics market is primarily driven by growing prevalence of Non-Hodgkin’s lymphomas (NHL) and other types of cancers around the world coupled with increasing expenditure on medical and healthcare infrastructure. Also, increasing awareness towards the effects of Non-Hodgkin’s lymphomas (NHL) and extensive R&D activities are acting as some other major drivers for this market. In addition to this, factors like the US Food and Drug Administration’s approval for chronic lymphocytic leukemia therapy drugs and increasing demand for innovative drugs and novel technologies are expected to drive the market growth through 2026.

Moreover, patent expiry of standard drugs, especially in untapped markets is anticipated to provide profitable growth opportunities for this market in near future. Apart from this, improved diagnostic techniques to detect NHL is fueling the growth of global Non-Hodgkin Lymphoma (NHL) therapeutics market. However, the market is also susceptible to some restraints. High cost of NHL drugs and stringent regulatory guidelines is anticipated to limit the market growth. Furthermore, various complications associated with NHL drugs are expected to hamper the global Non-Hodgkin Lymphoma (NHL) therapeutics market growth in coming years.

Browse 132 figures spread through 110 Pages and an in-depth TOC on "Global Non-Hodgkin Lymphoma Therapeutics Market"

https://www.techsciresearch.com/report/non-hodgkin-lymphoma-nhl-therapeutics-market/5113.html

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is segmented based on type of therapy, cell type, drug type, distribution channel and region. Based on type of therapy, the market can be segmented into immunotherapy, targeted therapy, chemotherapy, stem cell transplant, others. Among these, immunotherapy segment dominated the market in 2020 and is further projected to maintain its dominance in the next 5 years as well. This can be attributed to higher revenue realization by these drugs. Targeted therapy is anticipated to register highest growth in the market over the coming years owing to high accuracy of these therapies in targeting cancer.  In addition to this, presence of large number of targeted therapies for Non-Hodgkin Lymphoma (NHL) treatment is another factor which is further contributing to the high growth of this segment.

Regionally, North America dominated global Non-Hodgkin Lymphoma therapeutics market in 2020. High prevalence of Non-Hodgkin lymphoma (NHL) in the region and efforts by leading pharmaceutical companies to develop efficient treatment options is further expected to aid the market growth in North America during the forecast period. The second most dominating market is expected to be Europe on account of growing number of patients requiring treatment in the region and high usage of advanced therapeutics. However, Asia-Pacific is anticipated to undergo fastest growth through 2026 due to improving healthcare reimbursement policies and increasing prevalence of Non-Hodgkin lymphoma (NHL) among the population in the region.

Major players operating in the global Non-Hodgkin Lymphoma (NHL) therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc. The market is highly competitive and key market players are investing on R&D activities to introduce new and more effective products in global market.  

Download Sample Report  @ https://www.techsciresearch.com/sample-report.aspx?cid=5113

Customers can also request for 10% free customization on this report.

“Extensive R&D activities are the most important tool for the growth of Non-Hodgkin Lymphoma  therapeutics market, which is why, large number of pharmaceutical companies are engaged in these activities to develop innovative formulations. Also, availability of the biosimilars at a reduced price is leading to high growth in global Non-Hodgkin Lymphoma (NHL) therapeutics market,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2026” has evaluated the future growth potential of global Non-Hodgkin Lymphoma (NHL) therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global Non-Hodgkin Lymphoma (NHL) therapeutics market.

Browse Related Reports

Global Self-monitoring Blood Glucose Market By Type (Type 1, Type 2, Hyperglycemia ,Hypoglycemia), By Frequency (One, Four, Others), By Product (Glucometer, Software, Test Strips, Lancet), By End-User (Hospital, Personal Care), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/self-monitoring-blood-glucose-market/4607.html

Global Portable Ventilator Market, By Type (Invasive Ventilation, Non-Invasive Ventilation), By Mode (Pressure Mode Ventilation; Volume Mode Ventilation; Combined Mode Ventilation), By Application (Aeromedical; Pediatrics; Domiciliary Ventilation; Non-Invasive Ventilation), By End User (Hospital; Ambulance; Clinic; Rehabilitation Center; Others), By Region, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/portable-ventilator-market/4541.html

Global Oncology Drugs Market By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent), By Route of Administration (Oral, Intravenous, Subcutaneous, Others), By Gender (Male, Female), By Cancer Type (Lung Cancer, Stomach Cancer, Others), By Distribution Channel (Hospital Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2025

https://www.techsciresearch.com/report/oncology-drugs-market/4689.html#profile

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

[rootsanalysis-blog]

The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030

Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

 Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

 Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

 To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

 Key Market Insights

 Over 755 CAR-T cell therapies are currently approved / under development

Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.

 Currently, the focus is on developing product candidates to treat various types of cancers

Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

 Extensive efforts are underway to improve CAR constructs

Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

 China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals

In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

 Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020

More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).

Over USD 13 billion has been invested by both private and public investors, across more than 205 instances

It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

 The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030

Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

 To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html  

 Key Questions Answered

§  Who are the leading industry and non-industry players in this market?

§  What are the prevalent R&D trends in CAR-T cell therapies domain?

§  What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?

§  What are the challenges faced by stakeholders in this industry?

§  Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?

§  Who are the key investors in this domain?

§  Who are the key opinion leaders / experts that can help in driving product development efforts in this field?

§  What kind of partnership models are commonly adopted by industry stakeholders?

§  What kind of contract manufacturing support is available for CAR-T cell therapies?

§  What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?

§  What are the factors that are likely to influence the evolution of this upcoming market?

§  How is the current and future market opportunity likely to be distributed across key market segments?

  The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

 §  Disease indication

§  Non-Hodgkin lymphoma

§  Multiple myeloma

§  Chronic lymphocytic leukemia

§  Acute lymphoblastic leukemia

§  Follicular lymphoma

§  Mantle cell lymphoma

§  Hepatocellular carcinoma

§  Colorectal cancer

 §  Target antigens

§  CD19

§  BCMA

§  CD19, CD22

§  GPC3

§  EGFR

 §  Key Geographical Regions 

North America

Europe

Asia Pacific

Latin America

Middle East and     North Africa

Rest of the     World 

 The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:

§  Tim Oldham (Chief Executive Officer, Cell Therapies)

§  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)

§  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)

§  Miguel Forte (Chief Operating Officer, TxCell)

§  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)

§  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)

§  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)

§  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)

§  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)

§  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

 The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. 

§  Autolus

§  bluebird bio

§  CARsgen Therapeutics

§  Celgene (A Bristol Myers Squibb Company)

§  Cellectis

§  Cellular Biomedicine Group

§  Innovative Cellular Therapeutics

§  Iovance Biotherapeutics

§  Kite Pharma (A Gilead Sciences Company)

§  Kuur Therapeutics

§  Noile-Immune Biotech

§  Novartis

§  Shanghai Genechem

§  Sinobioway Cell Therapy

§  Takara Bio

§  Ziopharm Oncology

 For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com

 You may also be interested in the following titles:

1.     Global T-Cell Therapies Market (5th Edition), 2021 – 2030

2.     mRNA Therapeutics and Vaccines Market, 2020-2030

3.     Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

4.     Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030

  About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

  Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[wemresearch]

Biosimilars Market Demand, Size, Share, Scope & Forecast to 2030

The Global Biosimilar Market is expected to be valued at USD 159.02 Billion by 2030 from USD 15.6 Billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2030.

Medicines known as biologics or biological products are created using living organisms through extremely intricate production procedures. They must be handled and administered under strict supervision. The term "biologics" refers to a broad range of goods, including vaccines, therapeutic proteins, monoclonal antibodies, and cell and gene therapies. Biologics are used to prevent, treat, or cure a number of illnesses, such as cancer, diabetes, cystic fibrosis, chronic kidney disease, and autoimmune disorders. Biologics are at the cutting edge of scientific and biological research and may be able to treat a variety of illnesses for which there are no other effective treatments.

A biotherapeutic product that is extremely similar to a reference biologic medication is referred to as a biosimilar, also known as a follow-on biologic. It has a complicated molecular structure and is made from living things or cells. Manufacturers rely on regulatory authority authorisation to launch the production of biosimilars when the patent on a biologic medication expires. A biological medication must be demonstrated to be identical in terms of quality, safety, and efficacy in order to be labelled as a biosimilar. Biosimilars are more expensive than generic medications because their production needs greater investment in R&D and is more complicated.

Get Free Sample:- https://wemarketresearch.com/sample-request/biosimilars-market/5/

Global Biosimilar Market: Segment Analysis

Biosimilar Market segment based on Molecule

• Filgrastim

• Rituximab

Filgrastim injection is for the treatment of Neutropenia, that is low white blood cells in the body, which is caused by cancer medicines. It is a synthetic form of substance that is produced naturally in your body known as colony stimulating factor. Filgrastim helps the bone marrow in the body to make new white blood cells itself.

Rituximab is used to treat certain types of Cancer such as Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Lukemia. It slows or stops the growth of cancer cells. Some products of Rituximab are also used to treat the pain of Rheumatoid Arthritis and can also decrease swelling and pain of the joints.

Segmentation based on Indication Insights

Oncology

Female Infertility

Oncology is the largest segment in this market due to the availability of Biosimilar at a lower price than Innovation Biologics and a large number of cancer patients. The availability of Biosimilar in Oncology has reduced the prices and made cancer treatment more accessible and affordable. Due to the high prevalence of cancer, healthcare systems across the globe are more concentrated on reducing the burden of cancer by adopting cost effective treatment options.

Biologics are too expensive and cannot be afforded by everyone. Therefore, cost-effective and new Biosimilars are being manufactured in the market. In January 2016, Teva Pharmaceutical Industries Ltd. introduced Ovaleap, a biosimilar to GONAL-f (follitropin alfa) from Merck KGaA. The low cost of Biosimilars promotes patient trust and boosts the market growth.

Segmentation based on Manufacturing

Contract Manufacturing

In- house Manufacturing

Based on the type of manufacturing, the market is classified into in-house manufacturing and contract manufacturing. Amongst these, in-house manufacturing holds the majority of the market share.

Top Key Players:-

LG Life Sciences

Fresenius SE & Co. KGaA

Pfizer, Inc.

Hospira

STADA Arzneimittel AG

Dr. Reddy’s Laboratories Ltd.

Eli Lilly and Company

Genentech (Roche Group).

Synthon Pharmaceuticals, Inc.

Celltrion

Boehringer Ingelheim

Amgen, Inc.

Gedeon Richter PLC

Merck Serono (Merck Group)

Teva Pharmaceutical Industries Ltd.

Biocon Limited

Samsung Biologics

Biogen idec, Inc.

Coherus BioSciences

Viatris, Inc

Fujifilm Kyowa Kirin Biologics Co., Ltd.

Interested in purchasing this Report? Click here:- https://wemarketresearch.com/purchase/biosimilars-market/5/?license=single

Frequently Asked Questions (FAQ):

What is the impact of COVID-19 on the biosimilars market?

Who are the key players in the biosimilars market?

Which product segment dominates in the biosimilars market?

Which indication segment of the global biosimilars market is expected to witness the highest growth?

What is the market size for biosimilars market?

About We Market Research

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.

Contact Us:

We Market Research

Phone: +1(929)-450-2887

Email: sales@wemarketresearch.com  

Web: https://wemarketresearch.com/

[healthcare-market]

Impact of COVID-19 on CAR T-cell Therapy Market

CAR T-cell Therapy Market: Introduction

According to the report, the global CAR T-cell therapy market was valued at US$ 1.1 Bn in 2020 and is projected to expand at a CAGR of 30.6% from 2021 to 2031. CAR T-cell therapy is a recently approved treatment option for various types of cancer. CAR T cell therapy is provided by removing or harvesting T cells from a patient with cancer, transfecting the cells with CAR genes that are directed against the patient’s tumor type, expanding the modified T cell population, and reinfusing the cells back into the patient. Currently, Kymriah, Yescarta, Tecartus, Breyanzi, and ABECMA are the CAR T-cell therapy approved products for acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=83242

The global CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline. North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early adoption of new products, high prevalence rate of cancer, and presence of major players are expected to propel the CAR T-cell therapy market in North America. Asia Pacific is likely to be a highly lucrative market for CAR T-cell therapy during the forecast period. The market in the region is projected to expand at a high CAGR from 2021 to 2031.

Request for Analysis of COVID19 Impact on CAR T-cell Therapy Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=83242

Increase in Incidence of Cancer and Strong Product Pipeline to Drive Global Market

Increase in incidence of cancer and strong product pipeline are anticipated to boost the growth of the global CAR T-cell therapy market. According to the WHO, one in five people develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. According to the WHO, in 2020, around 544,352 new cases of non-Hodgkin lymphoma were recorded globally.

Strong product pipeline is a major factor driving the demand for CAR T-cell therapy products. For instance, Autolus Therapeutics plc has one innovative product, AUTO1, in phase I trial for treatment of adult acute lymphoblastic leukemia. AUTO1 contains obecabtagene autoleucel, which is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=83242

Axicabtagene Ciloleucel to Dominate CAR T-cell Therapy Market

In terms of product type, the global CAR T-cell therapy market has been classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others. The axicabtagene ciloleucel segment dominated the global CAR T-cell therapy market in 2020 and the trend is expected to continue during the forecast period. Yescarta is a product, which contains axicabtagene ciloleucel. Increase in demand for Yescarta in the treatment of diffuse large B-cell lymphoma and follicular lymphoma is likely to boost the growth of the segment during the forecast period. In October 2017, Kite Pharma, Inc. received the U.S. FDA approval for Yescarta for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Tisagenlecleucel was the second largest segment in terms of market share in 2020. Increase in demand for Kymriah for treatment of acute lymphoblastic lymphoma and product approval in different countries are likely to drive the segment.

Enquiry before Buying CAR T-cell Therapy Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83242

Diffuse Large B-cell Lymphoma to be Highly Lucrative

Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others. The diffuse large B-cell lymphoma segment dominated the CAR T-cell therapy market due to increase in incidence of diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Increase in number of cases of non-Hodgkin lymphoma is likely to propel the segment during the forecast period. According to WHO, globally, around 544,352 new non-Hodgkin lymphoma cases were recorded in 2020.

Hospitals to Emerge as Significant End-user

In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers. The hospitals segment led the global CAR T-cell therapy market in terms of revenue in 2020 and the trend is projected to continue during the forecast period. The hospitalization for cancer treatment is anticipated to boost the growth of the hospitals segment. Moreover, increase in use of CAR T-Cell therapy in the treatment of cancers contributes to the segment's large market share. The segment is driven by surge in number of cancer patients who visit hospital for treatment of cancer.

Buy now CAR T-cell Therapy Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=83242&ltype=S

North America to Dominate CAR T-cell Therapy Market

In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global CAR T-cell therapy market in 2020, followed by Europe. North America’s large market share can be ascribed to technologically advanced research and treatment platforms, increase in number of cancer patients, new product launches, and presence of major players. The CAR T-cell therapy market in Asia Pacific is anticipated to expand at a high CAGR from 2021 to 2031. This can be ascribed to the presence of developing countries with commercial hubs, expansion of business organizations, rise in awareness about CAR T-cell therapy, improvement in healthcare infrastructure, and increase in investments by companies.

Competition Landscape

The global CAR T-cell therapy market is consolidated due to limited approved products. Key players operating in the global market include Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc.

More Trending Reports by Transparency Market Research:

D-dimer Testing Market D-dimer tests are used for diagnosing conditions related broadly to deep vein thrombosis (DVT), pulmonary embolism, and disseminated intravascular coagulation (DIC). Among all the applications, the demand for the test for diagnosing DVT is prominent.

Pyrogen Testing Market North America dominated the global pyrogen testing market in 2018and the trend is anticipated to continue during the forecast period. New drug approvals by the Food and Drug Administration (FDA) and increase in demand for pyrogen testing for medical devices are expected to drive the pyrogen testing market in North America.

Conserving Devices Market While nasal cannulae for supplementary supply of oxygen is reliable and effective, it is very wasteful. To address this, oxygen conserving methodologies have emerged to improve the efficiency of oxygen delivery for patients requiring oxygen therapy. This is because oxygen conserving devices enable a high degree of portability, improve the efficiency of oxygen delivery, and lighten the load for these patients.

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Mr. Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

[zaras2424]

Natural Killer Cells Therapeutics Market Analysis and Forecasts Research Report 2021-2030

Natural killer (NK) cells, also known as large granular lymphocytes (LGL), are defined as a type of cytotoxic lymphocyte which is critical to the innate immune system in the human body. NK cells belong to the innate lymphoid cells (ILC) which is a rapidly expanding family in the world of biological cells. They represent 5% to 20% of all circulating lymphocytes in humans. They are useful in the treatment of various types of cancers. Hence, many scientists are conducting research to explore new possible uses of NK cells regarding medical treatment. Increase in medical research in the field of natural killer cells therapeutics is profusely driving the growth of global natural killer cells therapeutics market. In recent years, scientists have started to re-engineer T cells to attack evasive tumors and creating the first Chimeric antigen receptor (CAR)-T treatments. Many researchers have also started to seriously explore how to do the same with natural killers. Experiments have been carried out by attaching CARs for CD19 to natural killer cells. With the cells being injected into patients with either non-Hodgkin lymphoma or chronic lymphocytic leukemia, so far majority cases have been turned out to be positive as the tumors of majority patients vanished.

Access the Full Report @ https://www.absolutemarketsinsights.com/reports/Natural-Killer-Cells-Therapeutics-Market-2021---2029-862

Investments towards enhancing effectiveness of natural killer cells therapeutics showcases positive growth opportunities for the global natural killer cells therapeutics market over the forecast period. CAR T is a new cell-based cancer immunotherapy. To provide a therapeutic anti­cancer effect, NK cells do not need any kind of antigen-specific priming. The efficacy of CAR modified peripheral blood natural killer cells being used for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia has been proven. Due to the spread of the China-originated coronavirus disease 2019 (COVID-19) which is also known as SARS-CoV-2 (SARS stands for Severe Acute Respiratory Syndrome), the immunological characteristics of COVID-19 are being researched. In some countries, NK cells are being experimented with the methods of lymphopenia to minimize the damage that coronavirus can cause to patients. A research to find a method using natural killer cells therapeutics for COVID treatment can be a big opportunity for the global natural killer cells therapeutics market.

Key Findings of the Report:

The global natural killer cells therapeutics market is anticipated to reach US$ 6317.20 Mn by 2029 growing at a CAGR of 17% during the forecast period (2021-2029).

The NK cell therapies category in the global natural killer cells therapeutics market held the larger market share in 2020. NK cells are capable of recognizing a wide range of ligands. Each of these can induce a cytolytic response. NK cells can also be easily isolated and expanded ex vivo. This allows for their use in adoptive or autologous cell therapies.

Cancer emerged as a dominant category under therapeutic indication in the global natural killer cells therapeutics market. The potent innate immune system effectors for cancer treatment can be harnessed from natural killer cells therapeutics. For example, in anticancer therapy, the checkpoint immunotherapy targets inhibitory receptors of T cells and reverses their functional blocking.

The peripheral blood segment held the largest share in the global natural killer cells therapeutics market in 2020. A medical technique called leukapheresis has made it possible to harvest cells directly from the peripheral blood of a donor. In this technique, immune cells are separated out from red blood cells. Peripheral blood mononuclear cells (PBMCs) are the most common source of NK cells. It is possible to collect PBMCs through apheresis or a specific gravity centrifugal method such as Ficoll separation.

Considering the end users segment, the hospitals & clinics segment occupied the largest market share in 2020 and is also anticipated to witness highest CAGR during the forecast period.

In 2020, North America was the biggest regional market in the global natural killer cells therapeutics market due to advanced medical research that was carried out in the medical institutions located in USA and Canada. Developed medical sector, presence of key market players, and technological advancement supporting the medical research, are some of the prominent factors contributing to the market growth in this region.

Some of the major players operating in the global natural killer cells therapeutics market are Acepodia Inc., Affimed GmbH, Artiva Biotherapeutics Inc., Bellicum Phamaceuticals Inc., Cytovia Therapeutics, Dragonfly Therapeutics, EMERCell, Fate Therapeutics, Fortress Biotech Inc., Glycostem, ImmunityBio Inc., Innate Pharma S.A., Kiadis Pharma, Nkarta Inc., NKGen Biotech, NKMAX Co. Ltd., and ONK Therapeutics Limited amongst others.

Global Natural Killer Cells Therapeutics Market:

By Type

NK Cell Therapies

Antibody Directed NK Cell Therapies

By Therapeutic Indication

Cancer

Viral Infections

Autoimmune Diseases

Neurodegenerative Diseases

Others

By Source

Peripheral Blood

Umbilical Cord Blood

Induced Pluripotent Natural killer cells therapeutics (iPSC)

Others

By End Users

Hospitals & Clinics

Research Institutes

Others

By Region:

North AmericaS. Canada Mexico Rest of North America

EuropeFrance The UK Spain Germany Italy Nordic CountriesDenmark Finland Iceland Sweden Norway Benelux UnionBelgium The Netherlands Luxembourg Rest of Europe

Asia PacificChina Japan India New Zealand Australia South Korea Southeast AsiaIndonesia Thailand Malaysia Singapore Rest of Southeast Asia Rest of Asia Pacific

Middle East & AfricaSaudi Arabia UAE Egypt Kuwait South Africa Rest of Middle East & Africa

Latin AmericaBrazil Argentina Rest of Latin America

Contact Us:

Company: Absolute Markets Insights Email id: sales@absolutemarketsinsights.com Phone: +91-740-024-2424 Contact Name: Shreyas Tanna Website: https://www.absolutemarketsinsights.com

[heathcareforallworld]

Analyzing the Market Dynamics of Marginal Zone Lymphoma Treatments

Introduction

Marginal zone lymphoma (MZL) is a distinct type of non-Hodgkin lymphoma (NHL) characterized by the slow progression of the disease. MZL includes three subtypes: extranodal MZL, nodal MZL, and splenic MZL, each with unique clinical features and treatment approaches. The treatment landscape for MZL has evolved significantly, driven by advancements in medical research and increased awareness. This article delves into the market size, share, industry trends, and forecast for MZL treatment.

Market Size and Share

The global marginal zone lymphoma treatment market is witnessing steady growth due to the rising prevalence of MZL and advancements in treatment options. The market size is influenced by several factors, including the availability of novel therapies, increasing healthcare expenditure, and the growing aging population, which is more susceptible to MZL.

Marginal Zone Lymphoma Treatment Market Size was estimated at 2.12 (USD Billion) in 2023. The Marginal Zone Lymphoma Treatment Market Industry is expected to grow from 2.24(USD Billion) in 2024 to 3.5 (USD Billion) by 2032. The Marginal Zone Lymphoma Treatment Market CAGR (growth rate) is expected to be around 5.71% during the forecast period (2024 - 2032). The market share is dominated by key pharmaceutical companies that are heavily investing in research and development to introduce innovative treatment options.

Industry Trends

Targeted Therapies: The advent of targeted therapies has revolutionized the treatment of MZL. These therapies specifically target cancer cells, reducing damage to healthy cells and minimizing side effects. Examples include monoclonal antibodies and small molecule inhibitors.

Immunotherapy: Immunotherapy, which harnesses the body's immune system to fight cancer, is gaining traction in the MZL treatment market. Agents like checkpoint inhibitors and CAR-T cell therapy have shown promising results in clinical trials.

Personalized Medicine: Personalized medicine approaches are becoming increasingly important in MZL treatment. By tailoring treatments to individual genetic profiles, healthcare providers can improve efficacy and reduce adverse effects.

Combination Therapies: Combining different therapeutic modalities, such as chemotherapy, immunotherapy, and targeted therapies, is becoming a standard approach to enhance treatment outcomes and overcome resistance.

Biosimilars: The introduction of biosimilars offers cost-effective alternatives to expensive biologics, potentially increasing access to effective treatments for a broader patient population.

Key Players and Competitive Landscape

The MZL treatment market is highly competitive, with several key players striving to gain a significant market share. Leading companies in this space include Johnson & Johnson, Incyte ,MorphoSys, Bristol Myers Squibb, Celgene, AstraZeneca. These companies are focusing on strategic partnerships, mergers and acquisitions, and extensive R&D to stay ahead in the market.

Regional Analysis

North America: North America holds the largest share of the MZL treatment market, driven by advanced healthcare infrastructure, high healthcare expenditure, and a strong presence of major pharmaceutical companies. The U.S., in particular, is a key market due to its high prevalence of MZL and robust clinical research activities.

Europe: Europe is the second-largest market for MZL treatment, with countries like Germany, France, and the UK leading the charge. Favorable government policies and increasing investments in healthcare are boosting market growth in this region.

Asia-Pacific: The Asia-Pacific region is expected to witness the highest growth rate during the forecast period. Rapidly improving healthcare infrastructure, increasing awareness about MZL, and rising healthcare spending in countries like China and India are key factors driving this growth.

Latin America and Middle East & Africa: These regions are also showing potential for growth due to improving healthcare access and increasing investments in medical research.

Emerging Opportunities

Research and Development: Continuous research and development activities are crucial for the discovery of new treatment options. Investments in understanding the molecular and genetic basis of MZL are paving the way for novel therapies.

Clinical Trials: Conducting clinical trials for new drugs and therapies is essential for market growth. Companies are increasingly focusing on clinical trials to validate the efficacy and safety of their products.

Patient Support Programs: Implementing patient support programs can improve treatment adherence and outcomes. These programs provide patients with necessary information, financial support, and psychological assistance.

Digital Health Technologies: The integration of digital health technologies, such as telemedicine and electronic health records, can enhance patient management and streamline treatment processes.

Market Forecast

The future of the MZL treatment market looks promising, with significant advancements expected in the coming years. The market is projected to grow at a steady pace, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.

Technological Innovations: Continued innovations in biotechnology and pharmaceuticals will lead to the development of more effective and targeted therapies.

Expanding Indications: Expanding the indications for existing drugs and therapies can open new avenues for market growth.

Regulatory Approvals: Obtaining regulatory approvals for new treatments is crucial for market expansion. Companies are focusing on gaining approvals from major regulatory bodies like the FDA and EMA.

Collaborations and Partnerships: Strategic collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers will drive market growth and facilitate the development of innovative treatments.

Conclusion The marginal zone lymphoma treatment market is poised for substantial growth in the coming years, driven by advancements in medical research, increasing awareness, and rising healthcare expenditure. The market dynamics are influenced by several factors, including the introduction of targeted therapies, immunotherapy, and personalized medicine. Key players in the industry are focusing on strategic initiatives to gain a competitive edge and expand their market presence. With continuous innovations and emerging opportunities, the future of the MZL treatment market looks bright.

[blogaarti]

Oncology Drugs Market is Expected to Show a Favourable Growth During the Forecast Period (2021-2025)

According to the National Cancer Institute, cancer survival rates over a five-year period in the US have demonstrated a marked improvement to 70% in 2020 – mainly due to improved healthcare, public policy, and novel pharmaceutical therapies. Oncology therapy comprised approx. a fifth of worldwide branded pharmaceutical sales and the oncology drugs market has consistently demonstrated double-digit growth for some time now. 

For More Insights into the Market, Get a Sample Copy of this Report:

https://www.fairfieldmarketresearch.com/report/oncology-drugs-market/

Companies Concentrating Their Efforts on Five Oncology Indications For Bulk Revenue

Although there are 20 different indications in oncology, the vast majority of revenue is derived from a quarter of those. In 2020, multiple myeloma, prostate cancer, non-small cell lung cancer and non-Hodgkin’s lymphoma (NHL) consists of more than half the oncology drugs market. Most drugs treat various types of cancers with three being anti-PD antibodies. A few other common cancers include skin, pancreatic, thyroid, renal, soft tissue, and brain cancer with breast, lung, and colorectal cancer accounting for more than 50% of all diagnosis in women. 

Supply Chains Enable Transformation in Autologous Therapy in Oncology Drugs Market

RNA therapy, stem cell therapy, viral vectors, and cell therapy have been the buzzwords in the oncology drugs market with gene therapies leading to evermore complex supply chain and manufacturing processes – particularly for autologous therapies. Yescarta and Kymriah – two CAR-T cell therapies were approved for treating and diffuse large B-cell lymphoma and acute lymphocytic leukaemia respectively. The treatment and diagnostics regimen has progressed rapidly through precision medicine with approx. 160 oncology biomarkers authorized in 2019 and almost all of them against molecular targets. 4/5th of novel clinical assets are for marketed targets with four or more clinical competitors leading to quicker initial launches, shorter development cycles, and competitor therapies. 

Maximum Activity Witnessed in Oncology With Thrice Development Spend of Other Sectors

Innovation in the oncology sector has boomed with the highest number of novel FDA approvals in this dynamic field. The estimated clinical development spend is thrice that of any other therapy area in phase III trials in the US. Oncology is responsible for roughly 2/5th of total expenditure and a third of total pipeline approvals in the US. In addition, it is one of the most expensive therapeutic areas in the pharmaceutical industry providing immense opportunities for companies in the oncology drugs market. 

In Order to place the Purchase Query Click Here: sales@fairfieldmarketresearch.com

Dominance of Ten Companies in Oncology Drugs Market Unlikely to Erode Anytime Soon

The ten largest pharmaceutical companies have already declared oncology as a primary focus area of their R&D initiatives. There has been a flurry of M&A activity and strategic collaborations revolving around oncology drugs recently. In 2019, American giant Pfizer acquired Array BioPharma and Genmab and AbbVie entered into a strategic partnership to develop bispecific antibodies. The oncology drugs market is characterized by its oligopolistic nature with the top ten companies capturing 3/4th of the market value. The biggest companies are F. Hoffmann-La Roche AG (Roche), Celgene, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, AstraZeneca, Merck & Co., Novartis, AbbVie, and Astellas Pharma. In 2020, Roche alone held a quarter of the global oncology drugs market but this share should decline by 2026 as its key products lose their popularity amongst patients. 

Browse Our Latest Reports:  https://www.fairfieldmarketresearch.com/shop/

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[karishmamulani]

Immuno Oncology (I-O) Market Evolving Opportunities, Covid-19 Impact, Strategies And Forecast

The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026�� gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample

Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.

On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.

Buy Now : https://www.polarismarketresearch.com/checkouts/751

[techscimarketresearch]

Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research

Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.

According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.

Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.

Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.

Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399

Customers can also request for 10% free customization on this report.

“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.

Browse Related Reports:

Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techsciresearch]

Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research

Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.

According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.

Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.

Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.

Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399

Customers can also request for 10% free customization on this report.

“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.

Browse Related Reports:

Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[sandlerresearch]

Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026 published on

https://www.sandlerresearch.org/leukapheresis-market-by-product-devices-filters-columns-disposables-leukopak-mobilized-non-mobilized-indication-all-nhl-multiple-myeloma-application-research-therapeutic-end-user-h.html

Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026

“The global leukapheresis products market and the leukopaks market is projected to grow at a CAGR of 8.4% and 41.9% respectively.”

The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and  cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

“The leukapheresis disposables segment holds the highest market share, by product, in the leukapheresis products market, in the forecast period.”

On the basis of product, the leukapheresis market is broadly segmented into leukapheresis disposables and leukaphersis devices. Leukapheresis devices are further segmented into centrifugal devices and membrane separators. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.

“The centrifugal devices segment to grow at the highest CAGR in the leukapheresis devices market, in the forecast period.”

Based on type, the leukapheresis devices market is broadly segmented into centrifugal devices and membrane separators. Centrifugal devices segment is expected to grow at the higest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.

“Increasing adoption of leukapheresis products for development of cell-based immunotherapies to promote the growth of this segment in the forecast period.”      

Based on application, the leukapheresis products market is segmented into research and therapeutic applications. The research applications segment accounted for the largest share of the leukapheresis products market during the forecast period.  The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.

“In the leukapheresis products market by end user segment, blood component providers & blood centers segment holds the highest market share”

On the basis of end user, the leukapheresis products market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.

“In the leukopaks market by type, the diseased leukopaks segment is projected to grow at the highest rate in forecast period”

Based on type, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs.  In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“Acute Lymphocytic Leukemia  holds the largest share in the leukopaks market, by indication, in the forecast period”

Based on indication, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia). The acute lymphocytic leukemia segment accounts for the largest share of the leukopaks market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.

“Acute Lymphocytic Leukemia  holds the largest share in the leukopaks market, by indication, in the forecast period”

Based on indication, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs.  In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.

“The pharmaceutical and biotechnology companies segment to grow at the highest CAGR in the leukopaks market, by end user, in the forecast period”

By end user, the leukopaks market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Pharmacuetical and biotechnology companies are projected to grow at the highest CAGR in this market in the forecast period. Thi highest growth rate can be attributed to increasing collaboration of pharmaceutical companies with academic institutes, research centers, and hospitals for new drug development.

“North America holds the largest share in the leukaphereis and  leukopaks market, by region, in the forecast period”

The leukapheresis and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The large share of this region can be attributed to the increasing adoption of leukapheresis products for the development of leukoreduced plasma and leukoreduced RBCs, growing adoption of leukopaks as a source of primary cells for research applications, increasing number of clinical trials for the development of CAR T-cell therapy using leukopaks.

A breakdown of the primary participants for the leukapheresis market referred to for this report is provided below:

By Company Type: Tier 1–30%, Tier 2–25%, and Tier 3–45%

By Designation: C-level–40%, Director Level–35%, and Others–25%

By Region: North America–36%, Europe–26%, Asia Pacific–21%, Rest of the World – 17%

A breakdown of the primary participants for the leukopaks market referred to for this report is provided below:

By Company Type: Tier 1–40%, Tier 2–38%, and Tier 3–22%

By Designation: C-level–40%, Director Level–35%, and Others–25%

By Region: North America–39%, Europe–28%, Asia Pacific–22%, Rest of the World – 11%

The prominent players in the global leukapheresis and leukopaks market are Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).

Research Coverage:

The report analyzes the market for various leukapheresis and leukopaks product and their adoption pattern. It aims at estimating the market size and future growth potential of the global leukapheresis and leukopaks market and different segments such as product, application, indication, end user and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global leukapheresis products and leukopaks market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global leukapheresis products and leukopaks market

Market Development: Comprehensive information on the lucrative emerging regions by products, end user, and region

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global leukapheresis products and leukopaks market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global leukapheresis products and leukopaks market.